Founded in 1997, ChemoCentryx (CCXI) only recently went public in February 2012. The company currently has a pipeline of six small molecule drugs (three of which are partnered with GSK) that target specific chemokine receptors. Chemo-attractant cytokines, or chemokines, are chemical messengers involved in coordinating the body's inflammatory response to infection, irritation, or injury. Different combinations of chemokines and their respective receptors can direct different inflammatory responses. Chronic inflammation over a long period of time can lead to certain auto-immune diseases, including inflammatory bowel disease ("IBD"), rheumatoid arthritis ("RA"), diabetic nephropathy, multiple sclerosis, and others.
Supported by 490 issued or allowed patents (with expirations ranging from 2020 to 2029) and 225 patents pending, CCXI's pipeline...
Only subscribers can access this article, which is part of the PRO research library covering 3,554 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: